Infusion of a Lipid Emulsion in Healthy Men Decreases the Serotonergic Response
Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing co...
Saved in:
| Published in | Neuroendocrinology Vol. 95; no. 4; pp. 325 - 331 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
01.06.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0028-3835 1423-0194 1423-0194 |
| DOI | 10.1159/000333038 |
Cover
| Abstract | Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m 2 , were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. |
|---|---|
| AbstractList | Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m2, were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m(2), were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 plus or minus 5.0 years and BMI 22.6 plus or minus 1.9 kg/m2, were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 plus or minus 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 plus or minus 0.05 to 2.3 plus or minus 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 plus or minus 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 plus or minus 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. Copyright [copy 2012 S. Karger AG, Basel Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m(2), were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity.Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m(2), were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is elevated plasma free fatty acids (FFAs). We hypothesize that increasing plasma FFA by infusion of a lipid emulsion, may be a contributing component leading to decreased serotonergic responsivity in healthy young men. Ten lean healthy men, 23.6 ± 5.0 years and BMI 22.6 ± 1.9 kg/m2, were included. Serotonergic responsivity was assessed using the prolactin response to infusion with citalopram, a selective serotonin reuptake inhibitor, which is a validated tool to assess serotonergic tone. All participants received a lipid/heparin emulsion (Intralipid) infusion during 6 h. Saline infusion was used as a control. To evaluate a possible effect of heparin per se on prolactin, four out of the ten subjects also received heparin only during 6 h without the serotonergic challenge test. Plasma prolactin increased by 74.3 ± 15.5% during saline infusion. Intralipid infusion increased plasma FFA from 0.5 ± 0.05 to 2.3 ± 0.2 mmol/l (p < 0.001). The increase in plasma prolactin during Intralipid infusion was significantly lower (39.3 ± 10%; p < 0.001 compared to saline infusion). Heparin infusion per se increased plasma prolactin by 14.0 ± 1.9%. We found that during the Intralipid infusion with concomitant high plasma FFA levels the serotonergic response was decreased in healthy young men. Higher FFA levels may be the mediator of the decreased serotonergic response reported in patients with insulin resistance and obesity. Copyright © 2012 S. Karger AG, Basel [PUBLICATION ABSTRACT] |
| Author | Klein Twennaar, Christian F. Sondermeijer, Brigitte M. Kastelein, John J.P. Dallinga-Thie, Geesje M. Franssen, Eric J.F. Fliers, Eric Serlie, Mireille J. Stroes, Erik S.G. Twickler, Marcel T.B. Hutten, Barbara A. |
| Author_xml | – sequence: 1 givenname: Brigitte M. surname: Sondermeijer fullname: Sondermeijer, Brigitte M. – sequence: 2 givenname: Christian F. surname: Klein Twennaar fullname: Klein Twennaar, Christian F. – sequence: 3 givenname: John J.P. surname: Kastelein fullname: Kastelein, John J.P. – sequence: 4 givenname: Eric J.F. surname: Franssen fullname: Franssen, Eric J.F. – sequence: 5 givenname: Barbara A. surname: Hutten fullname: Hutten, Barbara A. – sequence: 6 givenname: Geesje M. surname: Dallinga-Thie fullname: Dallinga-Thie, Geesje M. – sequence: 7 givenname: Erik S.G. surname: Stroes fullname: Stroes, Erik S.G. – sequence: 8 givenname: Eric surname: Fliers fullname: Fliers, Eric – sequence: 9 givenname: Marcel T.B. surname: Twickler fullname: Twickler, Marcel T.B. – sequence: 10 givenname: Mireille J. surname: Serlie fullname: Serlie, Mireille J. email: m.j.serlie@amc.nl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22327404$$D View this record in MEDLINE/PubMed |
| BookMark | eNqN0TlPwzAUAGALgWg5BnaELLHAEPCVNB5ROaUiJI45cpKX1iWxg50M_fe4tHSoGJhs2d97escB2jXWAEInlFxRGstrQgjnnPB0Bw2pYDwiVIpdNCSEpRFPeTxAB97PA2OSs300YIyzkSBiiF6eTNV7bQ22FVZ4oltd4rumr3_etMGPoOputsDPYPAtFA6UB4-7GeA3cLYLhbipLvAr-NYaD0dor1K1h-P1eYg-7u_ex4_R5OXhaXwziQqejLqISRBVQlLC8ircgS7LyZmMk5KpsqQECqZyHudxKsuqlEJKyTmoRFVEEpHzQ3Sxyts6-9WD77JG-wLqWhmwvc8oYSJJuEzofyhlCRnFcaDnW3Rue2dCI0vFpaBpnAZ1tlZ93kCZtU43yi2y36kGcL0ChbPeO6iyQneqCxPtnNJ1yJUt95Zt9hYiLrcifpP-ZU9X9lO5KbiNXH9_A4hmnKo |
| CODEN | NUNDAJ |
| CitedBy_id | crossref_primary_10_1007_s11154_024_09895_9 crossref_primary_10_1111_jsm_12327 crossref_primary_10_1194_jlr_P027706 crossref_primary_10_1007_s11154_015_9322_3 |
| Cites_doi | 10.1016%2Fj.neuron.2006.06.004 10.1042%2FCS20010248 10.1016%2FS0022-3956%2802%2900102-4 10.1001%2Fjama.2008.711 10.1016%2Fj.diabet.2007.01.006 10.1016%2FS0306-4530%2899%2900026-8 10.1016%2FS0300-2977%2899%2900040-6 10.1007%2Fs00213-003-1763-9 10.1210%2Fjc.2005-1654 10.1016%2F0893-133X%2895%2900117-V 10.1016%2F0140-6736%2892%2992684-8 10.1126%2Fscience.1072327 10.1007%2Fs002130100729 10.1002%2Fjnr.490240311 10.2337%2Fdiabetes.51.2.271 10.1016%2Fj.pnpbp.2006.01.017 10.2337%2Fdb09-0138 10.1016%2F0006-8993%2889%2990133-9 10.1210%2Fen.139.5.2629 10.1038%2Fnm1201 10.1210%2Fen.138.1.196 10.1371%2Fjournal.pone.0006649 10.1172%2FJCI117252 10.2337%2Fdiabetes.53.10.2529 10.1007%2FBF02637059 10.1177%2F1073858407311100 10.2337%2Fdiabetes.37.8.1020 10.1210%2Fjc.2003-031295 10.1172%2FJCI5001 10.2337%2Fdb07-1702 10.2337%2Fdb06-0152 10.1017%2FS1461145704004602 10.1016%2Fj.jad.2006.08.027 10.1016%2Fj.biopsych.2006.10.001 10.1111%2Fj.1471-4159.1987.tb01021.x 10.1007%2Fs00213-004-2006-4 |
| ContentType | Journal Article |
| Copyright | 2012 S. Karger AG, Basel Copyright © 2012 S. Karger AG, Basel. Copyright (c) 2012 S. Karger AG, Basel |
| Copyright_xml | – notice: 2012 S. Karger AG, Basel – notice: Copyright © 2012 S. Karger AG, Basel. – notice: Copyright (c) 2012 S. Karger AG, Basel |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QR 7T5 7TK 7TO 7X7 7XB 88A 88E 88G 88I 8AF 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M2M M2P M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1159/000333038 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Psychology Database Science Database (Proquest) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest AP Science SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central Basic ProQuest Science Journals ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE Neurosciences Abstracts MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1423-0194 |
| EndPage | 331 |
| ExternalDocumentID | 2704988931 22327404 10_1159_000333038 333038 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | --- -~X .55 .GJ 0R~ 0~5 0~B 123 186 29N 30W 325 34G 36B 39C 3O. 3V. 4.4 53G 5RE 7X7 88A 88E 88I 8AF 8AO 8FE 8FH 8FI 8FJ 8UI AAYIC ABIVO ABJNI ABPAZ ABUWG ACCUC ACGFS ACGOD ACIWK ACNCT ACPRK ACPSR ADAGL ADBBV ADFRT ADGES AENEX AETEA AEYAO AFFNX AFJJK AFKRA AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BBNVY BENPR BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD EMB EMOBN F5P FB. FYUFA GNUQQ HCIFZ HMCUK HZ~ H~9 IAO IHR ISR IY7 J5H KUZGX L7B LK8 M0L M1P M2M M2P M7P N9A O1H O9- OVD PQQKQ PROAC PSQYO PSYQQ RIG RKO RXVBD S0X SV3 TEORI UJ6 UKHRP X7M XJT XOL ZGI ZKB ZXP AAYXX ABBTS ABWCG ACQXL AFSIO AHFRZ CITATION ITC PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QR 7T5 7TK 7TO 7XB 8FD 8FK FR3 H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS PUEGO Q9U 7X8 |
| ID | FETCH-LOGICAL-c367t-29e4f60802bf29ee12740b2956d2add10ec2ab35b589dfd9499933ea6af0904b3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-3835 1423-0194 |
| IngestDate | Fri Sep 05 02:46:12 EDT 2025 Thu Sep 04 18:17:59 EDT 2025 Sat Aug 23 14:52:11 EDT 2025 Thu Apr 03 07:01:08 EDT 2025 Thu Apr 24 23:04:33 EDT 2025 Tue Jul 01 04:47:18 EDT 2025 Thu Aug 29 12:04:43 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Obesity Intralipid Serotonergic challenge test Hypothalamic pituitary axis Serotonin Prolactin Free fatty acids |
| Language | English |
| License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses Copyright © 2012 S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c367t-29e4f60802bf29ee12740b2956d2add10ec2ab35b589dfd9499933ea6af0904b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 22327404 |
| PQID | 1023941858 |
| PQPubID | 41201 |
| PageCount | 7 |
| ParticipantIDs | proquest_journals_1023941858 proquest_miscellaneous_1024663961 proquest_miscellaneous_1021260755 crossref_citationtrail_10_1159_000333038 pubmed_primary_22327404 karger_primary_333038 crossref_primary_10_1159_000333038 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-06-00 |
| PublicationDateYYYYMMDD | 2012-06-01 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
| PublicationTitle | Neuroendocrinology |
| PublicationTitleAlternate | Neuroendocrinology |
| PublicationYear | 2012 |
| Publisher | S. Karger AG |
| Publisher_xml | – name: S. Karger AG |
| References | DeGeorge JJ, Noronha JG, Bell J, Robinson P, Rapoport SI: Intravenous injection of [1–14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. J Neurosci Res 1989;24:413–423.10.1002%2Fjnr.490240311 Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M: Obesity among outpatients with major depressive disorder. Int Jf Neuropsychopharmacol 2005;8:59–63.10.1017%2FS1461145704004602 Ambalavanar R, Morris R: Fluoro-Gold injected either subcutaneously or intravascularly results in extensive retrograde labelling of CNS neurones having axons terminating outside the blood-brain barrier. Brain Res 1989;505:171–175.10.1016%2F0006-8993%2889%2990133-9 Horbcek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999;24:785–797.10.1016%2FS0306-4530%2899%2900026-8 Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661–671.10766253 Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L: Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002;51:271–275.1181273210.2337%2Fdiabetes.51.2.271 Moeller O, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A: Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2005;37:261–262.10.1016%2FS0022-3956%2802%2900102-4 Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020–1024.329232210.2337%2Fdiabetes.37.8.1020 O’Shea D, Morgan DGA, Meeran K, Edwards CMB, Turton MD, Choi SJ, Heath MM, Gunn I, Taylor GM, Howard JK, Bloom CI, Small CJ, Haddo O, Ma JJ, Callinan W, Smith DM, Ghatei MA, Bloom SR: Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 1997;138:196–202.10.1210%2Fen.138.1.196 Attenburrow MJ, Mitter P, Whale R, Terao T, Cowen P: Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 2001;155:323–326.10.1007%2Fs002130100729 Farquharson J, Jamieson EC, Logan RW, Cockburn F, Ainslie Patrick W: Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet 1992;340:810–813.135724410.1016%2F0140-6736%2892%2992684-8 van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, Pijl H: Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 2004;53:2529–2534.10.2337%2Fdiabetes.53.10.2529</pub-id><pub-id pub-id-type="pmid">15448080 Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB: The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 2006;91:718–721.1630383410.1210%2Fjc.2005-1654 Migrenne S, Le Foll C, Levin BE, Magnan C: Brain lipid sensing and nervous control of energy balance. Diab Metab. Corrected proof, in press. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG: Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 2005;178:268–275.10.1007%2Fs00213-004-2006-4 Migrenne S, Magnan C, Cruciani-Guglielmacci C: Fatty acid sensing and nervous control of energy homeostasis. Diab Metab 2007;33:177–182.10.1016%2Fj.diabet.2007.01.006 Hawken ER, Owen JA, Van Vugt D, Delva NJ: Effects of oral racemic citalopram on neuroendocrine responses. Prog Neuro-Psychopharmacol Biol Psychiatry 2006;30:694–700.10.1016%2Fj.pnpbp.2006.01.017 Miller JC, Gnaedinger JM, Rapoport SI: Utilization of plasma fatty acid in rat brain: distribution of [14C]palmitate between oxidative and synthetic pathways. J Neurochem 1987;49:1507–1514.288980110.1111%2Fj.1471-4159.1987.tb01021.x Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS: Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300:2379–2388.1903358810.1001%2Fjama.2008.711 Boden G, Chen X, Ruiz J, White JV, Rossetti L: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438–2446.820097910.1172%2FJCI117252 Rapoport S: In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. Biomed Life Sci 2001;16:243–261. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253–259.991613710.1172%2FJCI5001 Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK: Activation of central melanocortin pathways by fenfluramine. Science 2002;297:609–611.1214253910.1126%2Fscience.1072327 Khan A, Schwartz KA, Kolts RL, Brown WA: BMI, sex, and antidepressant response. J Affect Dis 2007;99:101–106.10.1016%2Fj.jad.2006.08.027 Oury F, Karsenty G: Towards a serotonin-dependent leptin roadmap in the brain. Trends Endocrinol Metab. Corrected proof, in press. Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E, Thornton-Jones Z, Liu HY, Zigman JM, Balthasar N, Kishi T, Lee CE, Aschkenasi CJ, Zhang CY, Yu J, Boss O, Mountjoy KG, Clifton PG, Lowell BB, Friedman JM, Horvath T, Butler AA, Elmquist JK, Cowley MA: Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006;51:239–249.1684685810.1016%2Fj.neuron.2006.06.004 Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E: Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996;14:253–263.10.1016%2F0893-133X%2895%2900117-V Lam TKT, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Guilar-Bryan L, Schwartz GJ, Rossetti L: Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005;11:320–327.1573565210.1038%2Fnm1201 Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD: Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008;57:1482–1490.1833209510.2337%2Fdb07-1702 Karmi A, Iozzo P, Viljanen A, et al: Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010;59:2171–2177.10.2337%2Fdb09-0138 Flory JD, Manuck SB, Perel JM, Muldoon MF: A comparison of d,l-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology 2004;174:376–380.10.1007%2Fs00213-003-1763-9 Price CJ, Hoyda TD, Ferguson AV: The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008;14:182–194.10.1177%2F1073858407311100 Rapoport SI: In vivo labeling of brain phospholipids by long-chain fatty acids: relation to turnover and function. Lipids 1996;31:S97–S101.10.1007%2FBF02637059 Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M, Zihl J, Pfister H, Unschuld PG, Holsboer F, Lucae S: Overweight and obesity affect treatment response in major depression. Biolol Psychiatry 2007;62:321–326.10.1016%2Fj.biopsych.2006.10.001 Schwartz MW, Erickson JC, Baskin DG, Palmiter RD: Effect of fasting and leptin deficiency on hypothalamic neuropeptide Y gene transcription in vivo revealed by expression of a lacZ reporter gene. Endocrinology 1998;139:2629–2635.10.1210%2Fen.139.5.2629 Le Moli R, Endert E, Fliers E, Mulder T, Prummel MF, Romijn JA, Wiersinga WM: Establishment of reference values for endocrine tests. II. Hyperprolactinemia. Neths J Med 1999;55:71–75.10.1016%2FS0300-2977%2899%2900040-6 Kearney MT, Chowienczyk PJ, Brett SE, Sutcliffe A, Ritter JM, Shah AM: Acute haemodynamic effects of lipolysis-induced increase of free fatty acids in healthy men. Clin Sci 2002;102:495–500.10.1042%2FCS20010248 Marsollier N, Kassis N, Mezghenna K, Soty M, Fioramonti X, Lacombe Al, Joly Al, Pillot B, Zitoun C, Vilar J, Mithieux G, Gross R, Lajoix AD, Routh V, Magnan C, Cruciani-Guglielmacci C: Deregulation of hepatic insulin sensitivity induced by central lipid infusion in rats is mediated by nitric oxide. PLoS ONE 2009;4:e6649.10.1371%2Fjournal.pone.0006649 Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB: Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metab 2004;89:266–271.1471586010.1210%2Fjc.2003-031295 Pilegaard H, Birk JB, Sacchetti M, Mourtzakis M, Hardie DG, Stewart G, Neufer PD, Saltin B, van Hall G, Wojtaszewski JFP: PDH-E1{alpha} dephosphorylation and activation in human skeletal muscle during exercise: effect of intralipid infusion. Diabetes 2006;55:3020–3027.10.2337%2Fdb06-0152 ref13 ref35 ref12 ref34 ref15 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – reference: Ambalavanar R, Morris R: Fluoro-Gold injected either subcutaneously or intravascularly results in extensive retrograde labelling of CNS neurones having axons terminating outside the blood-brain barrier. Brain Res 1989;505:171–175.10.1016%2F0006-8993%2889%2990133-9 – reference: Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E, Thornton-Jones Z, Liu HY, Zigman JM, Balthasar N, Kishi T, Lee CE, Aschkenasi CJ, Zhang CY, Yu J, Boss O, Mountjoy KG, Clifton PG, Lowell BB, Friedman JM, Horvath T, Butler AA, Elmquist JK, Cowley MA: Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006;51:239–249.1684685810.1016%2Fj.neuron.2006.06.004 – reference: Lam TKT, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Guilar-Bryan L, Schwartz GJ, Rossetti L: Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 2005;11:320–327.1573565210.1038%2Fnm1201 – reference: Migrenne S, Le Foll C, Levin BE, Magnan C: Brain lipid sensing and nervous control of energy balance. Diab Metab. Corrected proof, in press. – reference: Kearney MT, Chowienczyk PJ, Brett SE, Sutcliffe A, Ritter JM, Shah AM: Acute haemodynamic effects of lipolysis-induced increase of free fatty acids in healthy men. Clin Sci 2002;102:495–500.10.1042%2FCS20010248 – reference: Oury F, Karsenty G: Towards a serotonin-dependent leptin roadmap in the brain. Trends Endocrinol Metab. Corrected proof, in press. – reference: Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB: The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 2006;91:718–721.1630383410.1210%2Fjc.2005-1654 – reference: DeGeorge JJ, Noronha JG, Bell J, Robinson P, Rapoport SI: Intravenous injection of [1–14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. J Neurosci Res 1989;24:413–423.10.1002%2Fjnr.490240311 – reference: Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020–1024.329232210.2337%2Fdiabetes.37.8.1020 – reference: Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M, Zihl J, Pfister H, Unschuld PG, Holsboer F, Lucae S: Overweight and obesity affect treatment response in major depression. Biolol Psychiatry 2007;62:321–326.10.1016%2Fj.biopsych.2006.10.001 – reference: Khan A, Schwartz KA, Kolts RL, Brown WA: BMI, sex, and antidepressant response. J Affect Dis 2007;99:101–106.10.1016%2Fj.jad.2006.08.027 – reference: Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB: Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metab 2004;89:266–271.1471586010.1210%2Fjc.2003-031295 – reference: Miller JC, Gnaedinger JM, Rapoport SI: Utilization of plasma fatty acid in rat brain: distribution of [14C]palmitate between oxidative and synthetic pathways. J Neurochem 1987;49:1507–1514.288980110.1111%2Fj.1471-4159.1987.tb01021.x – reference: Horbcek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999;24:785–797.10.1016%2FS0306-4530%2899%2900026-8 – reference: Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L: Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002;51:271–275.1181273210.2337%2Fdiabetes.51.2.271 – reference: van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, Pijl H: Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 2004;53:2529–2534.10.2337%2Fdiabetes.53.10.2529</pub-id><pub-id pub-id-type="pmid">15448080 – reference: Pilegaard H, Birk JB, Sacchetti M, Mourtzakis M, Hardie DG, Stewart G, Neufer PD, Saltin B, van Hall G, Wojtaszewski JFP: PDH-E1{alpha} dephosphorylation and activation in human skeletal muscle during exercise: effect of intralipid infusion. Diabetes 2006;55:3020–3027.10.2337%2Fdb06-0152 – reference: Le Moli R, Endert E, Fliers E, Mulder T, Prummel MF, Romijn JA, Wiersinga WM: Establishment of reference values for endocrine tests. II. Hyperprolactinemia. Neths J Med 1999;55:71–75.10.1016%2FS0300-2977%2899%2900040-6 – reference: Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK: Activation of central melanocortin pathways by fenfluramine. Science 2002;297:609–611.1214253910.1126%2Fscience.1072327 – reference: Marsollier N, Kassis N, Mezghenna K, Soty M, Fioramonti X, Lacombe Al, Joly Al, Pillot B, Zitoun C, Vilar J, Mithieux G, Gross R, Lajoix AD, Routh V, Magnan C, Cruciani-Guglielmacci C: Deregulation of hepatic insulin sensitivity induced by central lipid infusion in rats is mediated by nitric oxide. PLoS ONE 2009;4:e6649.10.1371%2Fjournal.pone.0006649 – reference: Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG: Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 2005;178:268–275.10.1007%2Fs00213-004-2006-4 – reference: Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD: Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008;57:1482–1490.1833209510.2337%2Fdb07-1702 – reference: Attenburrow MJ, Mitter P, Whale R, Terao T, Cowen P: Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 2001;155:323–326.10.1007%2Fs002130100729 – reference: Hawken ER, Owen JA, Van Vugt D, Delva NJ: Effects of oral racemic citalopram on neuroendocrine responses. Prog Neuro-Psychopharmacol Biol Psychiatry 2006;30:694–700.10.1016%2Fj.pnpbp.2006.01.017 – reference: Karmi A, Iozzo P, Viljanen A, et al: Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010;59:2171–2177.10.2337%2Fdb09-0138 – reference: Rapoport SI: In vivo labeling of brain phospholipids by long-chain fatty acids: relation to turnover and function. Lipids 1996;31:S97–S101.10.1007%2FBF02637059 – reference: Migrenne S, Magnan C, Cruciani-Guglielmacci C: Fatty acid sensing and nervous control of energy homeostasis. Diab Metab 2007;33:177–182.10.1016%2Fj.diabet.2007.01.006 – reference: Flory JD, Manuck SB, Perel JM, Muldoon MF: A comparison of d,l-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology 2004;174:376–380.10.1007%2Fs00213-003-1763-9 – reference: Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS: Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300:2379–2388.1903358810.1001%2Fjama.2008.711 – reference: Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E: Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996;14:253–263.10.1016%2F0893-133X%2895%2900117-V – reference: O’Shea D, Morgan DGA, Meeran K, Edwards CMB, Turton MD, Choi SJ, Heath MM, Gunn I, Taylor GM, Howard JK, Bloom CI, Small CJ, Haddo O, Ma JJ, Callinan W, Smith DM, Ghatei MA, Bloom SR: Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 1997;138:196–202.10.1210%2Fen.138.1.196 – reference: Boden G, Chen X, Ruiz J, White JV, Rossetti L: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438–2446.820097910.1172%2FJCI117252 – reference: Moeller O, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A: Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2005;37:261–262.10.1016%2FS0022-3956%2802%2900102-4 – reference: Price CJ, Hoyda TD, Ferguson AV: The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008;14:182–194.10.1177%2F1073858407311100 – reference: Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661–671.10766253 – reference: Schwartz MW, Erickson JC, Baskin DG, Palmiter RD: Effect of fasting and leptin deficiency on hypothalamic neuropeptide Y gene transcription in vivo revealed by expression of a lacZ reporter gene. Endocrinology 1998;139:2629–2635.10.1210%2Fen.139.5.2629 – reference: Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253–259.991613710.1172%2FJCI5001 – reference: Rapoport S: In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. Biomed Life Sci 2001;16:243–261. – reference: Farquharson J, Jamieson EC, Logan RW, Cockburn F, Ainslie Patrick W: Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet 1992;340:810–813.135724410.1016%2F0140-6736%2892%2992684-8 – reference: Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M: Obesity among outpatients with major depressive disorder. Int Jf Neuropsychopharmacol 2005;8:59–63.10.1017%2FS1461145704004602 – ident: ref35 doi: 10.1016%2Fj.neuron.2006.06.004 – ident: ref15 doi: 10.1042%2FCS20010248 – ident: ref14 doi: 10.1016%2FS0022-3956%2802%2900102-4 – ident: ref1 doi: 10.1001%2Fjama.2008.711 – ident: ref26 doi: 10.1016%2Fj.diabet.2007.01.006 – ident: ref6 doi: 10.1016%2FS0306-4530%2899%2900026-8 – ident: ref18 doi: 10.1016%2FS0300-2977%2899%2900040-6 – ident: ref7 doi: 10.1007%2Fs00213-003-1763-9 – ident: ref5 doi: 10.1210%2Fjc.2005-1654 – ident: ref11 doi: 10.1016%2F0893-133X%2895%2900117-V – ident: ref20 doi: 10.1016%2F0140-6736%2892%2992684-8 – ident: ref34 doi: 10.1126%2Fscience.1072327 – ident: ref10 doi: 10.1007%2Fs002130100729 – ident: ref23 doi: 10.1002%2Fjnr.490240311 – ident: ref29 doi: 10.2337%2Fdiabetes.51.2.271 – ident: ref12 doi: 10.1016%2Fj.pnpbp.2006.01.017 – ident: ref21 doi: 10.2337%2Fdb09-0138 – ident: ref27 doi: 10.1016%2F0006-8993%2889%2990133-9 – ident: ref31 doi: 10.1210%2Fen.139.5.2629 – ident: ref25 doi: 10.1038%2Fnm1201 – ident: ref30 doi: 10.1210%2Fen.138.1.196 – ident: ref36 doi: 10.1371%2Fjournal.pone.0006649 – ident: ref9 doi: 10.1172%2FJCI117252 – ident: ref32 doi: 10.2337%2Fdiabetes.53.10.2529 – ident: ref19 doi: 10.1007%2FBF02637059 – ident: ref28 doi: 10.1177%2F1073858407311100 – ident: ref8 doi: 10.2337%2Fdiabetes.37.8.1020 – ident: ref4 doi: 10.1210%2Fjc.2003-031295 – ident: ref16 doi: 10.1172%2FJCI5001 – ident: ref33 doi: 10.2337%2Fdb07-1702 – ident: ref17 doi: 10.2337%2Fdb06-0152 – ident: ref2 doi: 10.1017%2FS1461145704004602 – ident: ref24 doi: 10.1016%2Fj.jad.2006.08.027 – ident: ref3 doi: 10.1016%2Fj.biopsych.2006.10.001 – ident: ref22 doi: 10.1111%2Fj.1471-4159.1987.tb01021.x – ident: ref13 doi: 10.1007%2Fs00213-004-2006-4 |
| SSID | ssj0002932 |
| Score | 2.0078673 |
| Snippet | Subjects with obesity and insulin resistance display a low response to a serotonergic challenge test. One of the hallmarks of obesity and insulin resistance is... |
| SourceID | proquest pubmed crossref karger |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 325 |
| SubjectTerms | Adolescent Adult citalopram Citalopram - administration & dosage Citalopram - pharmacology Down-Regulation - drug effects Fat Emulsions, Intravenous - administration & dosage Fat Emulsions, Intravenous - pharmacology Fatty acids Fatty Acids, Nonesterified - blood Health Heparin Humans Infusion Pumps Insulin Insulin - blood Insulin Resistance - physiology Lipids Male Obesity Original Paper Prolactin Prolactin - blood Prolactin - metabolism Serotonin - blood Serotonin - metabolism Serotonin uptake inhibitors Serotonin Uptake Inhibitors - administration & dosage Serotonin Uptake Inhibitors - pharmacology Young Adult |
| Title | Infusion of a Lipid Emulsion in Healthy Men Decreases the Serotonergic Response |
| URI | https://karger.com/doi/10.1159/000333038 https://www.ncbi.nlm.nih.gov/pubmed/22327404 https://www.proquest.com/docview/1023941858 https://www.proquest.com/docview/1021260755 https://www.proquest.com/docview/1024663961 |
| Volume | 95 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB60FfEiPqrWR1lFxEswyWbzOImPigpVEQu9hU2yAbFNatMc-u-d3WyiB_UWNgOb7GPm-2ZnZwBOPcEZp4lvILblynVj8Dhmhs_kOZpPTaF8uoMn937oPI7YSDvcCh1WWetEpaiTPJY-8gtLFfFG6-JfTj8NWTVKnq7qEhrL0Fapy3A9e6OGcJloyuw6CzMyMaYzC6EFlxcYKFJ5eS3lhz1a-ZDh17O_0aayOncbsK7hIrmq5ncTlkS2BdtXGVLlyYKcERXAqTzjW7A60Ofk2_D8kKWl9IORPCWcyALVCelPyrFqe89IdftoQQYiI7cKORaiIAgGCSqPXCbonqFKJK9VBK3owPCu_3Zzb-jSCUZMXW9u2IFwUlfeo41SfBYWkk8zspEMJTZqNMsUsc0jyiLmB0mayAw1AaWCuzw1A9OJ6A60MuxrD4jpxTwOIuFwjtQjdbnn0dSyElkJMEp8qwvn9QCGsc4rLstbjEPFL1gQNmPdhZNGdFol0_hNqFPNQiNStx_WkxLqfVaE36uiC8fNa9wh8tiDZyIvlYyFrM1j7F8ZB7FX4OLv7FYT3nSPAEqOnrP__wccwBqCKbsKIzuE1nxWiiMELPOop1ZlD9rX_aeX1y9n1OaW |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZS8NAEB60ivoi3tZzFRVfgrk2x4OIR6VVW0Us-BY3yQZETbUH0j_lb3Rmc4igvvlW0iHHHjPfNzsHwI4rBRdW7GmIbYVy3WgiirjmcTpH8yxdKp9us-XU2_bFPb8fgY8iF4bCKgudqBR13InIR35gqCbeaF28o9c3jbpG0elq0UIjWxaXcviOlK132DjD-d01zfPa3Wldy7sKaJHluH3N9KWdOJRiGib4WxrIy_TQRJ4Qm7jZDV1GpggtHnLPj5OYircg6ZfCEYnu63Zo4X1HYcymjNYKjJ3UWje3pe5H42kWdZ-R-_G8lhFiBkqZsCw0GN43Czj-RAHf3d_xrbJz5zMwnQNUdpytqFkYkekczB-nSM5fhmyPqZBR5Yufg4lmfjI_D9eNNBmQ5411EiYYtcSOWe1l8KyuPaYsy3casqZM2ZnCqj3ZYwg_GaqrDpUE76ISZrdZzK5cgPa_DOsiVFJ81jIw3Y1E5IfSFgLJTuII17USw4ip92AYe0YV9osBDKK8kjk11HgOFKPhflCOdRW2S9HXrHzHT0IL2SyUIsX1tWJSgnxn94KvdViFrfJv3JN00CJS2RkoGQN5osv5nzI2oj3fwc9Zyia8fDxCNho9e-XvF9iEyfpd8yq4arQuV2EKoZyZBbGtQaXfHch1hEv9cCNfowwe_ntbfAKxCiMu |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8QwEB50FfEi6vpYXTWKipdi2zR9HETEdXHVXUUU9lbTNgFRu7oPZP-av85J-hBBvXkr6dBHksl832QyA7DrCc44TXwDsS3XrhuDxzEzfKb20XxqCu3TbXfc83vnosu6E_BRnIVRYZXFmqgX6qQXKx_5oaWLeKN18Q9lHhZx02gev74ZqoKU2mktymlkU-RSjN-Rvg2OWg0c6z3bbp7dnZ4beYUBI6auNzTsQDjSVcdNI4nXwkKOZkY2cobERsW3TBHbPKIsYn6QyEQlcgkoFdzl0gxMJ6L43EmY8iiiKtQlr1uSPRPNqF1kgEYWyPKsRoge1OEJStF0-N9s4fSTCv3u_450tcVrzsNcDlXJSTa3FmBCpItQPUmRpr-MyT7RwaPaK78IM-18j74K161UjpQPjvQk4UQVx07I2cvoWbc9piQ7-TQmbZGShkatAzEgCEQJLlw9lRy8j8sxuc2id8US3P9Lpy5DJcV3rQIxvZjHQSQczpH2SJd7HpWWlagqhFHiWzU4KDowjPOc5qq0xnOouQ0LwrKva7BTir5miTx-ElrKRqEUKdrrxaCEuY4Pwq8ZWYPt8jZqp9py4anojbSMhYzRY-xPGQdxX-Di76xkA16-HsGb6j1n7e8P2IIZVIbwqtW5XIdZxHR2Fs1Wh8qwPxIbiJuG0aaeoAQe_lsjPgErXiX1 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Infusion+of+a+Lipid+Emulsion+in+Healthy+Men+Decreases+the+Serotonergic+Response&rft.jtitle=Neuroendocrinology&rft.au=Sondermeijer%2C+Brigitte+M.&rft.au=Klein+Twennaar%2C+Christian+F.&rft.au=Kastelein%2C+John+J.P.&rft.au=Franssen%2C+Eric+J.F.&rft.date=2012-06-01&rft.issn=0028-3835&rft.eissn=1423-0194&rft.volume=95&rft.issue=4&rft.spage=325&rft.epage=331&rft_id=info:doi/10.1159%2F000333038&rft_id=info%3Apmid%2F22327404&rft.externalDocID=333038 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3835&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3835&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3835&client=summon |